TY - JOUR T1 - Estimating the impact of Angelman syndrome on parental productivity in Australia using productivity-adjusted life years JF - medRxiv DO - 10.1101/2021.06.03.21258279 SP - 2021.06.03.21258279 AU - Sally L Hartmanis AU - Emma K Baker AU - David E Godler AU - Danny Liew Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/11/2021.06.03.21258279.abstract N2 - Angelman syndrome (AS) is a severe neurodevelopmental condition associated with a significant socioeconomic impact. This is the first study to estimate the impact of AS on parental productivity in Australia using cost-of-illness modelling with simulated follow-up over a 10-year period using 2019 as the baseline year. Key data were obtained from a prospective cohort of AS families, peer-reviewed literature, and publicly-available sources. The base-case productivity burden borne by the estimated 330 living parents of the 428 prevalent-persons with AS totalled AUD$1.25 million, corresponding to a loss of 38.42% of PALYs per-parent. This shows that caring for a child with AS has a significant impact on the productivity of affected parents, with a large associated impact on the broader Australian economy.Competing Interest StatementE.K.B. and D.E.G. have received funding from the Foundation for Angelman Syndrome Therapeutics (FAST). The authors report that they have no other conflicts or competing interests relevant to the contents of this paper to disclose.Funding StatementThis study was supported by the Victorian Governments Operational Infrastructure Support Program, Next Generation Clinical Researchers Program Career Development Fellowship, funded by the Medical Research Future Fund (MRF1141334 to D.E.G.), and the Foundation for Angelman Syndrome Therapeutics (FAST Australia to E.K.B. and D.E.G.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Royal Childrens Hospital Human Research Ethics Committee (reference number 33066) and the Monash University Human Research Ethics Committee (reference number 20212593055113). All parents and or caregivers provided written informed consent and participants who were deemed cognitively able also provided written informed consent. The authors certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.ASAngelman syndromeCHEERSConsolidated Health Economic Evaluation Reporting StandardsCSRIClient Service Receipt InventoryDSDravet syndromeFTEfull-time equivalentPALYproductivity-adjusted life yearPDMAParticipant Developmental and Medical AnamnesisWPAIWork Productivity and Activity Impairment ER -